# OnCo record cassian-yee (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/cassian-yee/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "cassian-yee" ;
  schema:name "Cassian Yee"@en ;
  schema:alternateName "Cassian Yee, MD"@en, "C. Yee"@en ;
  schema:description "Cassian Yee is a cancer doctor and scientist in Houston who grows a patient's own cancer-recognising T cells in the laboratory and gives them back as a treatment. Cassian Yee's early trials in Seattle were among the studies that showed such cells can find and shrink melanoma."@en ;
  schema:url <https://onco.cc/people/cassian-yee/> ;
  schema:dateModified "2026-11-05"^^xsd:date ;
  schema:citation <https://faculty.mdanderson.org/profiles/cassian_yee.html>, <https://orcid.org/0000-0002-4429-7307> ;
  onco:tag "immunotherapy", "cell-therapy", "melanoma", "trialist" ;
  schema:jobTitle "Professor, Melanoma Medical Oncology and Immunology; Director, Program for T Cell-Based Therapies, MD Anderson Cancer Center" ;
  schema:sameAs <https://orcid.org/0000-0002-4429-7307> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/til-therapy/> ;
  onco:targets <https://onco.cc/targets/ctag1b/>, <https://onco.cc/targets/gp100/> ;
  onco:companies <https://onco.cc/companies/immatics/>, <https://onco.cc/companies/instil-bio/>, <https://onco.cc/companies/obsidian-therapeutics/>, <https://onco.cc/companies/genomefrontier-therapeutics/>, <https://onco.cc/companies/t-cypher-bio/>, <https://onco.cc/companies/affyimmune-therapeutics/>, <https://onco.cc/companies/berkeley-lights/>, <https://onco.cc/companies/lav/>, <https://onco.cc/companies/prellis-biologics/>, <https://onco.cc/companies/adaptive-biotechnologies/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/fred-hutch/>, <https://onco.cc/institutions/stanford/>, <https://onco.cc/institutions/princess-margaret/>, <https://onco.cc/institutions/rice-university/>, <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/oicr/>, <https://onco.cc/institutions/osu-james/>, <https://onco.cc/institutions/cancer-research-institute/>, <https://onco.cc/institutions/damon-runyon/>, <https://onco.cc/institutions/burroughs-wellcome-fund/>, <https://onco.cc/institutions/aacr/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/sitc/> ;
  onco:terms <https://onco.cc/terms/endogenous-t-cell-therapy/> ;
  onco:trials <https://onco.cc/trials/nct00002786/>, <https://onco.cc/trials/nct00045357/>, <https://onco.cc/trials/nct00045149/>, <https://onco.cc/trials/nct00317759/>, <https://onco.cc/trials/nct00101257/>, <https://onco.cc/trials/nct00438984/>, <https://onco.cc/trials/nct00553306/>, <https://onco.cc/trials/nct01106235/>, <https://onco.cc/trials/nct02210104/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-yee-ctl-clones-melanoma-pnas-2002/>, <https://onco.cc/key-papers/paper-yee-t-cell-vitiligo-jem-2000/>, <https://onco.cc/key-papers/paper-hunder-cd4-ny-eso-1-melanoma-nejm-2008/>, <https://onco.cc/key-papers/paper-wallen-fludarabine-ctl-melanoma-plos-one-2009/>, <https://onco.cc/key-papers/paper-chapuis-cd8-central-memory-melanoma-pnas-2012/>, <https://onco.cc/key-papers/paper-chapuis-il21-ctl-ipilimumab-jco-2016/>, <https://onco.cc/key-papers/paper-yee-endogenous-t-cells-immunol-rev-2014/>, <https://onco.cc/key-papers/paper-chu-pan-cancer-t-cell-atlas-nat-med-2023/>, <https://onco.cc/key-papers/paper-yee-endogenous-t-cell-therapy-cancer-j-2015/> ;
  schema:affiliation <https://onco.cc/institutions/md-anderson/> .